JPMorgan Chase & Co. assumed coverage on shares of Passage Bio (NYSE:GFL) in a research report sent to investors on Monday, Briefing.com Automated Import reports. The brokerage issued an overweight rating and a $19.00 target price on the stock.
GFL has been the subject of a number of other reports. CIBC began coverage on Passage Bio in a report on Monday. They set a neutral rating and a $27.00 price objective for the company. Goldman Sachs Group began coverage on Passage Bio in a report on Monday. They set a neutral rating for the company. Scotiabank began coverage on Passage Bio in a report on Monday. They set an outperform rating and a $23.00 price objective for the company. Raymond James began coverage on Passage Bio in a report on Monday. They set an outperform rating and a $18.00 price objective for the company. Finally, Barclays began coverage on Passage Bio in a report on Monday. They set an equal weight rating and a $20.00 price objective for the company. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has an average rating of Buy and an average price target of $21.38.
GFL stock traded down $0.60 during midday trading on Monday, hitting $13.14. The stock had a trading volume of 1,366,400 shares, compared to its average volume of 2,322,005. Passage Bio has a 52 week low of $13.00 and a 52 week high of $17.95.
GFL Environmental Inc operates as a diversified environmental services company in North America. The company offers non-hazardous solid waste management, infrastructure and soil remediation, and liquid waste management services. Its solid waste management business line includes the collection, transportation, transfer, recycling, and disposal of non-hazardous solid waste for municipal, residential, and commercial and industrial customers.
Featured Story: What is the Current Ratio?
Receive News & Ratings for Passage Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Passage Bio and related companies with MarketBeat.com's FREE daily email newsletter.